LONG-ACTING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISM MITIGATES INFLAMMATION AND FIBROSIS IN MODELS OF NASH AND BILIARY FIBROSIS

被引：0
|
作者：
Wang, X. -Y. [1 ]
Weng, S. -Y. [1 ]
Kim, Y. O. [1 ]
Klein, T. [2 ]
Schuppan, D. [1 ,3 ]
机构：
[1] Inst Translat Immunol, Mainz, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(14)60791-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P629
引用
收藏
页码：S278 / S278
页数：1
相关论文
共 50 条
  • [11] Elafibranor and Glucagon-Like Peptide-1 Receptor Agonists Synergize to Attenuate Hepatic Inflammation and Fibrosis in a Rodent Model of Obesity, Insulin Resistance, and NASH
    Legry, Vanessa
    Descamps, Emeline
    Debaecker, Simon
    Stankovic-Valentin, Nicolas
    Parroche, Peggy
    Degallaix, Nathalie
    Poulain, Philippe
    Staels, Bart
    Walczak, Robert
    DIABETES, 2020, 69
  • [12] Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist
    Pan, CQ
    Buxton, JM
    Yung, SL
    Tom, I
    Yang, L
    Chen, HX
    MacDougall, M
    Bell, A
    Claus, TH
    Clairmont, KB
    Whelan, JP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (18) : 12506 - 12515
  • [13] Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide
    Trautmann, Michael E.
    Choi, In Young
    Kim, Jung Kuk
    Sorli, Christopher H.
    DIABETES, 2018, 67
  • [14] Preclinical effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, compared with liraglutide and dulaglutide
    Trautmann, M.
    Choi, I.
    Kim, I.
    Sorli, C.
    DIABETOLOGIA, 2018, 61 : S346 - S346
  • [15] Glucagon-like peptide-1 receptor
    Krashes, Michael
    CURRENT BIOLOGY, 2024, 34 (23) : R1163 - R1164
  • [16] Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities
    Han, Jing
    Fei, Yingying
    Zhou, Feng
    Chen, Xinyu
    Zhang, Ying
    Liu, Lin
    Fu, Junjie
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (03) : 544 - 557
  • [17] The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro
    Bregenbolt, S
    Moldrup, A
    Blume, N
    Karlsen, AE
    Friedrichsen, BN
    Tornhave, D
    Knudsen, LB
    Petersen, JS
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 330 (02) : 577 - 584
  • [18] Long-Acting Glucagon-Like Peptide 1 Receptor Agonists A review of their efficacy and tolerability
    Garber, Alan J.
    DIABETES CARE, 2011, 34 : S279 - S284
  • [19] Glucagon-like peptide-1 receptor (GLP-1R) agonism ameliorates non-alcoholic steatohepatitis (NASH) in rodent models
    Roth, J. D.
    Trevaskis, J. L.
    Griffin, P. S.
    Wittmer, C.
    Neuschwander-Tetri, B. A.
    Brunt, E. M.
    Dolman, C. S.
    Erickson, M. R.
    Parkes, D. G.
    DIABETOLOGIA, 2011, 54 : S109 - S109
  • [20] In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist
    Jones, Ben
    Burade, Vinod
    Akalestou, Elina
    Manchanda, Yusman
    Ramchunder, Zenouska
    Carrat, Gaelle
    Nguyen-Tu, Marie-Sophie
    Marchetti, Piero
    Piemonti, Lorenzo
    Leclerc, Isabelle
    Thennati, Rajamannar
    Vilsboll, Tina
    Thorens, Bernard
    Tomas, Alejandra
    Rutter, Guy A.
    DIABETES OBESITY & METABOLISM, 2022, 24 (11): : 2090 - 2101
12345